Imagination at work.

Imaging Perspective
GE Healthcare

Jan Wolber
EFPIA Annual Meeting, 5 June 2015

Imagination at work.
GE Healthcare

$17 Bn global business unit of GE

53,000 employees worldwide

$1 Bn annual investment in R&D

Core strengths in biomedical sciences, technology & business

Serving healthcare systems • hospitals • clinics • governments • pharmaceutical & biopharmaceutical industries • genetics & bio-science researchers • academia
GE Healthcare Life Sciences

Accelerating precision medicine with tools for biotechnology R&D, biopharma manufacturing, cell therapy & regenerative medicine, diagnostic imaging, molecular & precision diagnostics

Five product business units • 10 000 people • 100+ countries • UK HQ Manufacturing, research & development in US, Europe and Asia
β-Amyloid PET Imaging in Dementia: The Need for an Innovation Ecosystem
VIZAMYL™: β-Amyloid PET Imaging Agent

Aβ PET imaging indicates Aβ neuritic plaque density

**Negative Scan**
- None or sparse plaque deposition
- Decreases AD likelihood
- Inconsistent with diagnosis of AD

**Positive Scan**
- Moderate or frequent plaque deposition
- May be present in other neurological conditions
- May be present in older people with normal cognition
- Is an adjunct to clinical evaluations

---


**CHMP VIZAMYL opinion/EMA press release**

“The benefits with Vizamyl are its ability to help detect with a high accuracy the beta-amyloid deposition, and therefore contribute valuable additional information in the diagnostic process in Alzheimer’s disease.”
β-Amyloid PET Imaging – The Challenges
Individual stakeholders have different needs

**Regulatory authorities**
Require evidence to support patient management and diagnostic workflow

**GE Healthcare**
- Need to demonstrate utility of β-amyloid PET imaging
- Difficult to gain reimbursement without disease-modifying treatments

**Pharmaceutical industry**
- Are developing drugs targeting β-amyloid
- Need to stratify populations
- Need outcome measures
- Looking for suitable biomarkers

**Payers**
Need to see added value of PET imaging; looking for health-economic benefits

**Other β-amyloid PET providers**
Similar needs to GEHC

**Clinicians**
- Have medical need for unequivocal diagnosis
- Seeking to improve patient outcomes

**Academia**
- Conducting clinical research
- Seeking access to imaging agents
- Developing other biomarkers

Stakeholders need each other; impossible to create a win-win situation alone
Establishing Utility of β-Amyloid PET Imaging
Vision of an integrated approach

Synergistic value proposition:
• Joined-up approach between EFPIA companies, Partners in Research and other collaborators
• Addressing cross-industry needs (consortium of several EFPIA and PiR entities)
• Potential for therapeutic & diagnostic co-development
• Economies of scale
• Enabling synergies with existing programmes (e.g. clinical cohorts)
• Potential for joint interactions with regulators and payers

Integration of imaging component through ‘Partners in Research’ mechanism